JW Pharmaceutical

Investors

JW, creating results with world-class technology and competitiveness

Summary of consolidated statements of financial position

(Unit : one million won, as of K-IFRS separate financial statements )

Category	2019	2020	2021	2022
Current assets	335,057	299,329	366,452	425,457
Non-current assets	238,150	249,756	266,602	202,516
Total assets	573,209	549,085	633,053	627,973
Current liabilities	277,983	234,748	282,678	380,131
Non-current liabilities	65,134	106,870	161,836	22,083
Total liabilities	343,117	341,618	444,514	402,214
Capital	54,092	55,616	57,202	59,418
Capital surplus	99,341	97,817	96,629	104,358
Elements of Other equities	-10,146	-10,371	-10,783	-11,065
Retained Earnings	86,789	71,543	58,595	89,130
Total equitles	230,092	207,467	188,539	225,759

Summary of separate financial statements

(Unit : one million won, as of K-IFRS separate financial statements )

Category	2019	2020	2021	2022
Current assets	327,582	287,700	348,367	361,770
Non-current assets	240,827	249,224	204,759	207,046
Total assets	568,409	536,924	553,126	568,816
Current liabilities	275,062	223,633	268,241	306,448
Non-current liabilities	65,024	106,684	78,572	13,474
Total liabilities	340,086	330,317	346,813	319,922
Capital	54,092	55,616	57,202	59,418
Capital surplus	99,341	97,817	96,629	104,413
Elements of Other equities	-10,146	-10,371	-10,783	-11,064
Other Comprehensive Income/Loss	9	-70	-70	-70
Retained Earnings	85,207	63,614	63,334	96,197
Total equitles	228,323	206,607	206,313	248,894